USPSTF Recommendations and Overdiagnosis
Journal of Breast Imaging · 2024
DOI: 10.1093/jbi/wbae028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Breast Imaging, 2024. Verfasst von R Edward Hendrick und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Colorado Anschutz School of Medicine, Aurora, CO, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammography, Early Detection of Cancer, Overdiagnosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
Overdiagnosis is the concept that some cancers detected at screening would never have become clinically apparent during a woman’s lifetime in the absence of screening. This could occur if a woman dies of a cause other than breast cancer in the interval between mammographic detection and clinical detection (obligate overdiagnosis) or if a mammographically detected breast cancer fails to progress to clinical presentation. Overdiagnosis cannot be measured directly. Indirect methods of estimating overdiagnosis include use of data from randomized controlled trials (RCTs) designed to evaluate breast cancer mortality, population-based screening studies, or modeling. In each case, estimates of overdiagnosis must consider lead time, breast cancer incidence trends in the absence of screening, and accurate and predictable rates of tumor progression. Failure to do so has led to widely varying estimates of overdiagnosis. The U.S. Preventive Services Task Force (USPSTF) considers overdiagnosis a major harm of mammography screening. Their 2024 report estimated overdiagnosis using summary evaluations of 3 RCTs that did not provide screening to their control groups at the end of the screening period, along with Cancer Intervention and Surveillance Network modeling. However, there are major flaws in their evidence sources and modeling estimates, limiting the USPSTF assessment. The most plausible estimates remain those based on observational studies that suggest overdiagnosis in breast cancer screening is 10% or less and can be attributed primarily to obligate overdiagnosis and nonprogressive ductal carcinoma in situ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, University of Colorado Anschutz School of Medicine, Aurora, CO, USA.
- Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
ORCID-Profile: R Edward Hendrick
Zitieren
APA
Hendrick, R. E., & Monticciolo, D. L. (2024). USPSTF Recommendations and Overdiagnosis. Journal of Breast Imaging. https://doi.org/10.1093/jbi/wbae028
Vancouver
Hendrick RE, Monticciolo DL. USPSTF Recommendations and Overdiagnosis. Journal of Breast Imaging. 2024. doi:10.1093/jbi/wbae028
BibTeX
@article{Hendrick2024,
author = {Hendrick, R Edward and Monticciolo, Debra L},
title = {USPSTF Recommendations and Overdiagnosis},
journal = {Journal of Breast Imaging},
year = {2024},
doi = {10.1093/jbi/wbae028}
}
EUVIMED